Sanuwave Health Stock Price, News & Analysis

Sanuwave Health (NASDAQ: SNWV), a provider of non-invasive wound care solutions, has been selected for inclusion in the Russell 2000® Index as part of the 2025 Russell indexes reconstitution, effective June 30. The company will also be included in the broader Russell 3000® Index and Russell Microcap® Index.

The Russell indexes, which capture the 4,000 largest U.S. stocks by market capitalization, are widely used by investment managers and institutional investors, with approximately $10.6 trillion in assets benchmarked to these indexes as of June 2024. Membership in these indexes remains in place for one year.

Sanuwave Health specializes in regenerative medicine products for wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions through their patented energy transfer technologies.

Sanuwave Health (NASDAQ:SNWV) has appointed Greg Bazar to its Board of Directors. Bazar brings extensive experience in engineering, computer science, cybersecurity, AI, and business intelligence. He currently serves as Chairman of Simpatico Systems and was previously instrumental at 3D-P, leading to its acquisition by Epiroc. The appointment comes as board member Michael Stolarski steps down, though he will remain as a consultant to assist with the transition.

Bazar's appointment aligns with Sanuwave's focus on interdisciplinary leadership and its evolution beyond therapeutics into informational ecosystems. His background in technology and cybersecurity is expected to contribute to the company's future roadmap in wound care solutions.

Sanuwave Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss their Q1 2025 financial results on Friday, May 9, 2025, at 8:30 AM ET.

Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Materials will be available on the company's investor website, and a replay will be accessible until May 30, 2025, using the replay access ID: 11158734.

SANUWAVE Health (NASDAQ: SNWV) reported preliminary Q1 2025 revenues of $9.1-9.3 million, marking the highest Q1 revenue in company history. This represents a 57-61% increase compared to Q1 2024.

The company's UltraMIST product line showed exceptional performance with a 65% growth versus Q1 2024, contributing to approximately 99% of total revenues. The strong performance came despite a transition period involving new sales leadership and sales force restructuring.

The company manufactures all UltraMIST systems and applicators domestically, insulating it from current tariff concerns. Full Q1 2025 results are expected to be released around May 9, 2025.

SANUWAVE Health (NASDAQ: SNWV) reported record-breaking financial results for Q4 and full year 2024. Q4 revenues reached $10.3 million, up 47% year-over-year, with a gross margin of 77.9%. Full-year 2024 revenues hit $32.6 million, increasing 60% from 2023.

Key Q4 highlights include:

• 135 UltraMist® systems sold (up from 79 in Q4 2023)
• UltraMist® consumables revenue grew 59% to $5.9 million
• Operating income of $2.5 million, up 143%
• Adjusted EBITDA of $3.7 million

For 2025, SANUWAVE projects Q1 revenue of $8.4-9.0 million (45-55% YoY growth) and full-year revenue guidance of $48-50 million (47-53% growth). The company completed a 1-for-375 reverse stock split and raised $10.3 million through private placement in Q4 2024.

SANUWAVE Health (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, has scheduled a conference call to discuss its Q4 and Full Year 2024 financial results. The call will take place on March 21, 2025, at 8:30 AM ET.

Investors can access the call through toll-free (1-800-245-3047) or international (1-203-518-9765) numbers using Conference ID: SANUWAVE. Supporting materials will be available on the company's investor relations website. A replay of the call will be accessible through April 11, 2025, using the replay access ID: 11157832.

Sanuwave Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, has announced its approval for listing on the Nasdaq Global Market. The company's common stock will begin trading on Nasdaq on March 7, 2025, maintaining its current ticker symbol 'SNWV'.

The transition from OTCQB to Nasdaq represents a significant milestone for Sanuwave after 18 months of transition and progress. Stockholders are not required to take any action regarding the uplisting. CEO Morgan Frank expressed enthusiasm about joining one of the world's premier stock exchanges, highlighting the company's goal of transforming the wound care market and creating shareholder value.

SANUWAVE Health (OTCQB: SNWV) announced its participation in the 37th Annual Roth Conference, scheduled for March 16-18, 2025, at the Laguna Cliffs Marriott Resort & Spa in Dana Point, California. CEO Morgan Frank will be available for one-on-one meetings with investors throughout the conference.

The Annual Roth Conference is one of the nation's largest small-cap company events, featuring approximately 500 private and public companies from various growth sectors. The conference format includes company presentations, Q&A sessions, and management meetings, covering sectors such as consumer, healthcare, industrial growth, sustainability, and technology.

SANUWAVE Health specializes in non-invasive medical systems for skin, musculoskeletal tissue, and vascular structure regeneration. The company's wound care portfolio utilizes patented energy transfer technologies to support natural healing processes across wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular applications.